Deal Announcement
13th of November, 2025 - Uppsala, Sweden
Rubicon Healthcare Partners Invests in PeptiSystems to Accelerate Global Expansion in Peptide and Oligonucleotide Manufacturing
Oslo, Norway – Rubicon Healthcare Partners (“Rubicon”), a growth-oriented investment firm focused on Nordic life science companies supplying products, services, and technologies to the healthcare and biopharmaceutical industries, today announces a significant growth investment in PeptiSystems, a life science company developing advanced manufacturing solutions for peptide- and oligonucleotide-based therapeutics.
Through this investment, Rubicon will become the largest shareholder in PeptiSystems following completion of the transaction. The partnership reflects Rubicon’s strategy of supporting high-quality Nordic life science platforms with strong technology foundations, scalable business models, and global market potential.
PeptiSystems has established a differentiated, best-in-class instrument portfolio designed to enable efficient and scalable manufacturing of therapeutic peptides and oligonucleotides. The company has demonstrated increasing commercial traction and is now advancing toward large-scale industrial applications, supporting customers in the transition to GMP production.
“We are proud to partner with PeptiSystems and support their robust growth strategy,” says Ole J. Dahlberg, Managing Partner at Rubicon Healthcare Partners. “The company’s strong values, commitment to excellence, and strategic vision align closely with our investment philosophy. We were particularly attracted to PeptiSystems’ innovative flow-through technology platform, customer-centric approach, and experienced management team.”
The investment will enable PeptiSystems to accelerate its global commercial expansion and further strengthen its organization to meet growing demand from the rapidly expanding biopharma market. Rubicon will contribute active ownership, strategic guidance, and access to its Nordic and international life science network to support the company’s next phase of development.
“We are pleased to welcome Rubicon Healthcare Partners as a new shareholder,” says Karin Granath, CEO of PeptiSystems. “Their global life science experience and Nordic presence will be a valuable asset as we continue to drive commercialization and scale our technology for industrial applications.”
Mats Johnson, Chairman of the Board of PeptiSystems, adds: “We welcome Rubicon as a major shareholder. This investment strengthens our ability to accelerate growth and further expand the adoption of our unique flow-through technology for the production of therapeutic peptides and oligonucleotides.”
The transaction is subject to customary closing conditions, including review under Sweden’s Foreign Direct Investment screening legislation.